Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Blue Chips Underperform On Big Earnings Day

Wed, 27th Apr 2016 11:13

LONDON (Alliance News) - Shares in the UK were mixed Wednesday midday, with large-cap stocks under-performing mid- and small-caps and with a US Federal Reserve interest rate decision due after the London market close.

Shares in blue-chip bank Barclays were slightly lower after its first-quarter earnings issued prior to the market open, while those of drug-making giant GlaxoSmithKline were flat after reporting at midday an "encouraging" start to 2016.

The FTSE 100 index was down 0.4%, or 21.91 points, at 6,262.61 at midday. At the same time, the FTSE 250 was up 0.4% at 17,016.66 and the AIM All-Share was flat at 729.44.

In Paris, the CAC 40 index was up 0.2%, and the DAX 30 in Frankfurt was adding 0.4%.

"Risk aversion is once more creeping into European markets as last week's gains are eroded away ahead of tonight's Federal Open Market Committee announcement," said IG analyst Joshua Mahony, noting that "it comes as no surprise that some element of profit taking should take hold with such a significant risk event ahead of us."

The Fed monetary policy decision is scheduled for 1900 BST. Economists overwhelmingly expect the central bank to leave its Federal Funds rate target unchanged, but a calmer global macroeconomic backdrop could mean the Fed hints at a rate rise at its next meeting in June.

IG's Mahony said that, with markets implying the chances of a rate hike stand at 0% probability and a rate cut at 2%, the interesting part of the meeting will be the tone of the Fed's statement with regards to future rate hikes. Mahony added that, with a 21% probability of a June rate hike, the Fed "will want to align expectations with the likeliness of it happening".

Following technology giant's Apple report of a drop in profit in the second-quarter, hurt largely by a double-digit revenue decline that reflected weak iPhone sales, the US corporate calendar brings on Wednesday first-quarter results from Facebook after the Wall Street close.

Wall Street futures were down, with the Dow 30 pointed down 0.2% and the S&P down 0.3%. The Nasdaq 100 was likely to suffer most from the results reported by Nasdaq-listed Apple Tuesday after the US equities close, called down 1.1%.

In the economic calendar, US goods trade balance is due at 1330 BST, pending home sales at 1500 BST, and the Energy Information Administration's crude oil stocks change at 1430 BST.

In addition to the Fed this week is a Bank of Japan policy decision set for early Thursday. The Japanese central bank will conclude its two-day policy meeting, with analysts widely expecting it to announce a slew of measures to help weaken the yen.

The UK economy grew at a slower pace, as expected, in the first quarter, preliminary estimates from the Office for National Statistics showed. Gross domestic product grew 0.4%, from a quarter ago, when it expanded 0.6%. This was in line with expectations.

Output increased in the dominant services sector by 0.6%. The other three main industrial groupings within the economy decreased, with production falling by 0.4%, construction output by 0.9% and agriculture by 0.1%.

On a yearly basis, UK GDP grew 2.1% in the first quarter, slightly faster than the expected growth of 2.0%.

"This is not a cause for concern," said Berenberg analyst Kallum Pickering, noting that it was anticipated. "The slowdown was caused by largely idiosyncratic and transitory risks, namely the financial market rout at the start of the year and the forthcoming EU referendum on June 23."

Another report from the ONS showed the UK index of services rose 2.5% in February from last year, with the largest contribution coming from distribution, hotels and restaurants and business services and finance. Month-on-month, services output edged up 0.1%, the same pace of growth as in January.

The pound gyrated heavily before and after the economic data, with sterling reaching an intraday high of USD1.4621 prior and then declining to a low of USD1.4550 shortly afterwards. The pound stabilized by midday, quoted at USD1.4600.

On the London Stock Exchange, Worldpay Group was up 2.6%, benefiting from an upgrade by UBS to Buy from Neutral. The Swiss bank said Worldpay's exposure to online transactions and significant investment in new value-added services will enable the company to outgrow its peers.

Shares in events and business publishing company Informa were up 1.2%, supported by an upgrade by Barclays to Overweight from Equal Weight.

Barclays itself was having an intense day following its first-quarter earnings. The bank said the results showed a core business in rude health even as the bank saw a 25% drop in pretax profit.

Pretax profit fell to GBP793 million in the three months ended March 31, Barclays said, down from GBP1.06 billion the corresponding quarter a year earlier, with income net of insurance claims down 11% to GBP5.04 billion and credit impairment charges up 15% to GBP443 million. The results were ahead of analyst expectations, reflecting a strong performance in the bank's core business and resilience in its investment banking business.

"In our view, the results reflect relative resilience, with notable outperformance versus peers in investment banking where revenues fell just 6% Q1/Q1," said Investec. Meanwhile, Jefferies said: "Barclays' first-quarter is uncontroversial in our view. The overall message is that the new CEO is executing well on plans, and we do not see consensus estimates moving either way."

Shares in Barclays opened higher Wednesday, reaching 182.00 pence, their highest level since early-February. However, the stock has declined since, trading down 0.5% at 173.10p at midday.

Emerging-market-focused peer Standard Chartered was down 3.5%, among the worst blue-chip performers, having been downgraded to Sell from Hold by Deutsche Bank. The stock was giving back only part of its gains on Tuesday, when it added 9.8%, reaching its highest level in 2016, after its first-quarter loan impairment charges and capital strength proved better than the market had expected.

Amec Foster Wheeler was up 3.2%, among the best performers in the FTSE 250. The company said it has appointed Jonathan Lewis, who has held several senior roles at US giant Halliburton, as its new chief executive as the company reported a drop in revenue in the first quarter of 2016.

The FTSE 250-listed oilfield services company said Lewis will takeover as chief executive from the start of June. Current interim Chief Executive Ian McHoul will step down from his role but remain as Amec Foster Wheeler's chief financial officer.

McCarthy & Stone was down 5.4% after funds managed by Anchorage Capital, TPG Special Situations Partners, Goldman Sachs European Special Situations Group and Strategic Value Partners sold 85.0 million shares in the retirement housebuilder, increased from the 75.0 million they had initially planned to sell.

The gross proceeds from the sale to the selling investors were around GBP200.0 million. Following the sale, Anchorage holds a 7.6% stake, TPG a 3.9% stake, Goldman Sachs a 3.9% stake and Strategic Value Partners a 4.2% stake.

Transport company Stagecoach Group was down 3.5% after saying like-for-like revenue grew in the first 48 weeks of its financial year in most of its operations, with only its North American arm suffering a decline. However, Liberum said that although revenue growth trends at the other divisions appear similar to the last update, "we see downside risk to 2017 estimates. Combined with bus re-regulation risk and looming rail franchise renewals, caution is still warranted."

Specialty chemicals company Elementis was down 1.5%. The group said it was working to manage its margins to keep its performance in line for 2016 following a mixed start to the year. The company said sales for its coatings and personal care segments in its Specialty Products division were "satisfactory" in the first quarter to the end of March, but total sales were down 7.0% amid a slump in oilfield revenue.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.